Advertisement
IOVA vs VIR
Which Stock Would AI Choose? Iovance Biotherapeutics (IOVA) vs. Vir Biotechnology (VIR) Stock Comparison
Key Takeaways
- Both IOVA and VIR are clinical-stage biotechs in immuno-oncology, but VIR shows stronger year-to-date gains of 79.6% versus IOVA's 28.9%.
- IOVA benefits from commercial traction of its FDA-approved Amtagvi (lifileucel) therapy for melanoma, with analyst targets up to $16.
- VIR gained momentum from a $1.71 billion Astellas collaboration on its prostate cancer T-cell engager VIR-5500, including first patient dosing.
- VIR exhibits higher volatility with a beta of 1.66 compared to IOVA's 0.76 (beta measures stock sensitivity to market movements).
- Analyst price targets imply significant upside for both: IOVA average $9, VIR $20.78.
Introduction
This comparison examines IOVA and VIR, two biopharmaceutical firms advancing immuno-oncology treatments amid a dynamic biotech sector. Investors and traders tracking cellular therapies and infectious disease innovations may find value here, as both stocks reflect shifting sentiment driven by clinical milestones and partnerships. With biotech relative performance influenced by regulatory progress and market positioning, understanding their trajectories aids in evaluating momentum trades or longer-term holdings in this high-growth area.
IOVA Overview and Recent Performance
Iovance Biotherapeutics (IOVA) develops tumor infiltrating lymphocyte (TIL) therapies, with its lead product Amtagvi approved for advanced melanoma. The company is expanding commercialization while advancing trials in lung cancer and other solid tumors. In recent market activity, IOVA shares rallied significantly over six months on Amtagvi's uptake, achieving year-to-date gains of 28.9% amid a current price around $3.52 and market cap of $1.45 billion. Sentiment has been buoyed by strong analyst support, including Buy ratings and price targets to $16, though shares dipped post-earnings. Influences include real-world data on Amtagvi efficacy and pipeline catalysts like NSCLC (non-small cell lung cancer) readouts.
VIR Overview and Recent Performance
Vir Biotechnology (VIR) focuses on immunotherapies, pivoting toward oncology with T-cell engagers (TCEs) targeting solid tumors like prostate cancer, alongside infectious disease programs. Recent weeks saw robust gains, with shares at $10.83 and a $1.75 billion market cap, delivering 79.6% year-to-date returns. Key drivers include closing a global Astellas collaboration worth up to $1.71 billion for VIR-5500 and dosing the first patient in Phase 1 trials, sparking positive sentiment. Analyst upgrades, like HC Wainwright's $20 target, underscore pipeline potential despite higher volatility.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases 25 top-performing bots curated from over 350 AI trading agents that manage thousands of tickers across stocks, ETFs, and crypto. These bots employ diverse strategies like trend trading, multi-agent long/short approaches, and sector-specific plays in semiconductors, gold miners, and small caps, with timeframes from 5 minutes to 60 days. Standout stats include annualized returns up to 175.94%, win rates of 53.89% to 87.72%, profit factors to 11.70, and profit-to-drawdown ratios exceeding 21. Many outperform the S&P 500, offering automated signals for volatile markets. Traders can explore these high-conviction options to align with current conditions.
Head-to-Head Comparison
IOVA’s TIL-based model emphasizes personalized cell therapies for solid tumors, contrasting VIR’s shift to masked TCEs and prior monoclonal antibodies for oncology and virology. Growth drivers differ: IOVA leverages Amtagvi commercialization, while VIR gains from partnerships like Astellas. Recent momentum favors VIR with superior returns and trial advances, versus IOVA’s steadier post-approval ramp. Risks include clinical setbacks for both, but VIR’s higher beta signals greater swings. Sector exposure aligns in biotech, yet sentiment tilts toward VIR’s catalysts amid oncology enthusiasm.
Tickeron AI Verdict
Tickeron’s AI currently leans toward VIR, citing consistent upward trends, a landmark Astellas deal, superior YTD performance, and advancing prostate cancer trials as stronger relative positioning in the immuno-oncology landscape. While IOVA offers Amtagvi stability, VIR’s momentum suggests higher probability of near-term outperformance based on observable factors.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IOVA is a Hold and VIR is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IOVA’s FA Score shows that 0 FA rating(s) are green whileVIR’s FA Score has 1 green FA rating(s).
- IOVA’s FA Score: 0 green, 5 red.
- VIR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IOVA’s TA Score shows that 5 TA indicator(s) are bullish while VIR’s TA Score has 5 bullish TA indicator(s).
- IOVA’s TA Score: 5 bullish, 5 bearish.
- VIR’s TA Score: 5 bullish, 4 bearish.
Price Growth
IOVA (@Biotechnology) experienced а +16.17% price change this week, while VIR (@Biotechnology) price change was +11.15% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +5.83%. For the same industry, the average monthly price growth was +1.96%, and the average quarterly price growth was +1945.11%.
Reported Earning Dates
IOVA is expected to report earnings on Aug 06, 2026.
VIR is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Biotechnology (+5.83% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| IOVA | VIR | IOVA / VIR | |
| Capitalization | 1.98B | 1.71B | 116% |
| EBITDA | -311.23M | -460.62M | 68% |
| Gain YTD | 62.553 | 58.706 | 107% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 286M | 64.7M | 442% |
| Total Cash | 313M | 476M | 66% |
| Total Debt | 47.8M | 95.6M | 50% |
IOVA | VIR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 61 | 18 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 41 Fair valued | 56 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 99 | 99 | |
PRICE GROWTH RATING 1..100 | 40 | 41 | |
P/E GROWTH RATING 1..100 | 100 | 33 | |
SEASONALITY SCORE 1..100 | 90 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
IOVA's Valuation (41) in the Biotechnology industry is in the same range as VIR (56) in the null industry. This means that IOVA’s stock grew similarly to VIR’s over the last 12 months.
IOVA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as VIR (100) in the null industry. This means that IOVA’s stock grew similarly to VIR’s over the last 12 months.
IOVA's SMR Rating (99) in the Biotechnology industry is in the same range as VIR (99) in the null industry. This means that IOVA’s stock grew similarly to VIR’s over the last 12 months.
IOVA's Price Growth Rating (40) in the Biotechnology industry is in the same range as VIR (41) in the null industry. This means that IOVA’s stock grew similarly to VIR’s over the last 12 months.
VIR's P/E Growth Rating (33) in the null industry is significantly better than the same rating for IOVA (100) in the Biotechnology industry. This means that VIR’s stock grew significantly faster than IOVA’s over the last 12 months.
| IOVA | VIR | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 81% | 2 days ago 84% |
| Stochastic ODDS (%) | 2 days ago 80% | 2 days ago 80% |
| Momentum ODDS (%) | 2 days ago 88% | 2 days ago 79% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 77% |
| TrendWeek ODDS (%) | 2 days ago 88% | 2 days ago 77% |
| TrendMonth ODDS (%) | 2 days ago 83% | 2 days ago 81% |
| Advances ODDS (%) | 12 days ago 78% | 12 days ago 74% |
| Declines ODDS (%) | 8 days ago 87% | 16 days ago 81% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 83% |
| Aroon ODDS (%) | 2 days ago 86% | 2 days ago 80% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| PSIL | 21.47 | 0.12 | +0.56% |
| AdvisorShares Psychedelics ETF | |||
| UNIY | 48.44 | 0.03 | +0.05% |
| WisdomTree Voya Yld Enh USD Unvsl Bd Fd | |||
| FUMB | 20.09 | -0.02 | -0.10% |
| First Trust Ultra Short Dur Muncpl ETF | |||
| XOVR | 19.61 | -0.23 | -1.16% |
| ERShares Private-Public Crossover ETF | |||
| FRWD | 32.51 | -1.69 | -4.95% |
| Nomura Transformational Technologies ETF | |||
VIR and
Correlation & Price change
A.I.dvisor indicates that over the last year, VIR has been loosely correlated with BEAM. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if VIR jumps, then BEAM could also see price increases.
| Ticker / NAME | Correlation To VIR | 1D Price Change % | ||
|---|---|---|---|---|
| VIR | 100% | +4.48% | ||
| BEAM - VIR | 55% Loosely correlated | +4.07% | ||
| PCVX - VIR | 53% Loosely correlated | +1.30% | ||
| DNLI - VIR | 52% Loosely correlated | +3.17% | ||
| XNCR - VIR | 50% Loosely correlated | +10.84% | ||
| RCUS - VIR | 50% Loosely correlated | +12.01% | ||
More | ||||